Fisher Biosciences unit, Cellomics, and Evotec Technologies Sign License Agreement
Companies to collaborate on cell-biology solutions for life-science markets
Advertisement
Cellomics, Inc., a business unit within the Fisher Biosciences group, and Evotec Technologies GmbH announced that they have entered into a worldwide, non-exclusive patent license agreement. The agreement will provide Evotec Technologies with Cellomics' core High Content Screening (HCS) patent portfolio, which includes both broad claims to HCS technology and specific classes of HCS assays such as cytoplasm-nuclear translocation, characterization of cellular toxicity, and receptor internalization. This is a significant extension of the portfolio of cellular biology applications for Evotec Technologies in the area of automated high-throughput HCS systems.
Evotec Technologies and Cellomics are also collaborating to develop and market combined offerings incorporating Cellomics' and Evotec Technologies' products as seamless solutions. This offering will enable cell biologists to obtain the highest quality, most productive results in their drug discovery, systems biology and high content screening efforts.
The two companies will improve the compatibility and integration of their software and assay products, including validation of Cellomics' assay kits by Evotec Technologies. Additional efforts will bring two-way data flow between the complementary platforms and access to enterprise-wide data storage, management, and analysis.
Financial details of the agreement were not disclosed.
Most read news
Topics
Organizations
Other news from the department business & finance
These products might interest you

Image Integrity Checker by Cytiva
Image integrity checker software - authenticate your images for publication
Safeguard and verify your image data with our free software

Limsophy by AAC Infotray
Optimise your laboratory processes with Limsophy LIMS
Seamless integration and process optimisation in laboratory data management

ERP-Software GUS-OS Suite by GUS
Holistic ERP solution for companies in the process industry
Integrate all departments for seamless collaboration

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Celera:Carriers of a Gene Variant are at Elevated risk of Coronary Heart Disease Which is Virtually Eliminated by Statin Therapy - New studies in more than 30,000 individuals indicate that carriers of the KIF6 gene variant have up to a 55% increased risk of a coronary event
Scientists have discovered how to predict life of implants without animal testing
Baxter and Cerus Halt Red Blood Cell Clinical Trials for Investigational Pathogen Inactivation System
UofL receives Bill and Melinda Gates Foundation Grand Challenges TB biomarkers grant
Nottinghamshire_Deaf_Society
In lab research, scientists limit autistic behavior

LabChip® GXII Touch™ | Protein analyzers | Revvity

Pinpointing neurons that tell the brain when to stop drinking
New £5.5 million R&D Programme to develop new predictive models for preclinical drug development
Actelion and Roche enter into autoimmune disorder collaboration
Mutations in gene linked to ciliopathies
